Committee

To download the Program Committee brochure here.


  • Alan Wright, MD

    Dr. Wright is the Chief Medical Officer at Roche Diagnostics Corporation in Indianapolis, Indiana. Prior to joining Roche, Dr. Wright served as Senior Vice President of Health Improvement Strategies for Miraca Life Sciences. He was the Vice President for Product Strategy and ...

    See more See less
  • Alan Maisel, MD

    Dr. Alan Maisel attended University of Michigan Medical School and did his cardiology training at the University of California at San Diego. He is currently Professor of Medicine at the University and director of the coronary care unit and the heart failure program at the ...

    See more See less
  • Ariel Louwrier PhD

    Successful Senior Scientific Business Executive with demonstrated expertise growing markets, revenues, product pipelines and expanding technical organizations into new business opportunities. Educational and business management experience in global markets, with quantified ...

    See more See less
  • C Jimmy Lin, MD, PhD, MHS

    Jimmy Lin, MD, PhD, MHS, is a 2012 TED Fellow and Founder & President of Rare Genomics Institute, the world's first platform to enable any community to leverage cutting-edge biotechnology to advance understanding of any rare disease. Partnering with 18 of the top medical ...

    See more See less
  • Agnieszka Lichanzka Ph.D.

    Agnieszka is currently a Staff Scientist and Laboratory Manager at TessArae, LLC in Sterling, VA, USA. She obtained her PhD at the University of Queensland in Australia in a field of biochemistry, and subsequently worked as a post-doctoral fellow at Queen's University of Belfast ...

    See more See less
  • Martin Latterich, PhD

    The discovery of proteinaceous disease biomarkers and their clinical validation is critically important for the enablement of molecular diagnostics and ultimately, precision medicine. In spite of the importance of biomarkers, research done in the last two decades has yielded ...

    See more See less
  • Fred Russell Kramer, PhD

  • Kamisha Johnson-Davis, PhD, DABCC, FACB

    Dr. Johnson-Davis is a medical director of the Clinical Toxicology laboratory, Antifungal Testing and Immunosuppressants Testing at ARUP. Dr. Johnson-Davis received her PhD in pharmacology at the University of Utah and is board certified in clinical chemistry by the American ...

    See more See less
  • Daniel Irimia, MD, PhD

  • Bruce Hollis, PhD

    Bruce W. Hollis, Ph.D. received his B.Sc. and M.Sc. from the Ohio State University and subsequently his Ph.D. from the University of Guelph in 1979. Dr. Hollis then completed an Endocrine Fellowship at The Case Western Reserve University School of Medicine in 1982. Dr. Hollis ...

    See more See less
  • Michael Holick, MD, PhD

    Michael F. Holick, Ph.D., M.D. is Professor of Medicine, Physiology and Biophysics; Director of the General Clinical Research Unit; and Director of the Bone Health Care Clinic and the Director of the Vitamin D, Skin and Bone Research Laboratory at Boston University Medical ...

    See more See less
  • Mark Marzinke, PhD, BABCC

    Mark Marzinke, PhD, DABCC earned a Ph.D. in Biochemistry from the University of Wisconsin-Madison and subsequently completed a clinical chemistry fellowship at The Johns Hopkins University in 2012. During his clinical fellowship, Dr. Marzinke focused on the development and ...

    See more See less
  • Vincent Mauro, Ph.D.

    Dr. Mauro is an Associate Professor in the Department of Neurobiology at the Scripps Research Institute in La Jolla, California. He is also a co-founder and lead scientist of Promosome, a biotechnology company focused on bioproduction enablement and DNA vaccines. In addition, Dr ...

    See more See less
  • Ross J Molinaro, PhD, MT(ASCP), DABCC, FACB

    Ross J. Molinaro, PhD, MT(ASCP), DABCC, FACB is an Assistant Professor in the Department of Pathology and Laboratory Medicine at Emory University. He received his PhD in Clinical Chemistry and Molecular Medicine from Cleveland State University and completed the ComACC training ...

    See more See less
  • Kathryn Wellen, PhD

  • Bart C. Weimer, PhD

  • Sihe Wang, PhD DABCC FACB

    Dr. Sihe Wang is Section Head and Medical Director of Clinical Biochemistry and Director of Clinical Biochemistry Fellowship Training Program, Cleveland Clinic, Cleveland, Ohio. He also chairs the clinical chemistry integration effort for the Cleveland Clinic Health System which ...

    See more See less
  • Theral Timpson

  • Deanne Taylor, MS, PhD

    Dr. Taylors background is in biophysics, bioinformatics, computational biology and structural biology with emphasis on human genetics and translational medicine. She obtained her Ph.D. in Biophysics from the University of Michigan, Ann Arbor, and completed a postdoctoral ...

    See more See less
  • Joely Straseski, PhD, MS, MT(ASCP), DABCC

    Dr. Straseski is a medical director of endocrinology at ARUP Laboratories and an assistant professor of pathology at the University of Utah School of Medicine. She received her PhD in pathology and laboratory medicine and a Master's degree in bacteriology from the University of ...

    See more See less
  • Amy K Saenger, PhD, DABCC, FACB

  • John Quackenbush, PhD

    John Quackenbush received his PhD in 1990 in theoretical physics from UCLA working on string theory models. Following two years as a postdoctoral fellow in physics, Dr. Quackenbush applied for and received a Special Emphasis Research Career Award from the National Center for ...

    See more See less
  • Judd Moul, MD, FACS

    Judd W. Moul is James H. Semans, MD Professor of Surgery, Division of Urologic Surgery, and Director of the Duke Prostate Center, Duke Cancer Institute at Duke University Medical Center. Prior to joining Duke, he was Professor of Surgery at the Uniformed Services University of ...

    See more See less
  • Howard Morris, PhD, FAACB, FFSc(RCPA)

    Professor Howard Morris is Professor of Medical Sciences at the University of South Australia and a Chief Medical Scientist in Chemical Pathology at SA Pathology, Adelaide, South Australia. He is currently Vice-President of the International Federation of Clinical Chemistry ...

    See more See less
  • Timothy Harris, PhD

    Since June 2011, Dr. Harris has served as the Senior Vice President of Translational Medicine at Biogen Idec. Dr. Harris has served as the Director of the Advanced Technology Program at SAIC Frederick since 2007 and Chief Technology Officer for SAIC Frederick since 2008. Prior to ...

    See more See less
  • Sharon Geaghan, MD

    Dr. Geaghan is Chief, Pathology at Lucile Packard Children's Hospital at Stanford, and Co-Director of Clinical Laboratories at Stanford Hospital and Clinics. She also directs the Bass Pediatric Cancer Center Laboratory at the Lucile Packard Hospital; is Director of the Point of ...

    See more See less
  • Stephanie Willerth, PhD

    Dr. Willerth currently holds a Canada Research Chair in Biomedical Engineering at the University of Victoria where she is dually appointed in the Department of Mechanical Engineering and Division of Medical Sciences. Her research group investigates how to engineer neural tissue ...

    See more See less
  • Katerina Venderova, PharmD, PhD

    Dr. Katerina Venderova obtained her master's and doctorate degrees in pharmacy, and her PhD in Toxicology from Charles University in the Czech Republic. She then received a fellowship from the Parkinson Society Canada and pursued her postdoctoral training at Toronto Western ...

    See more See less
  • Ahmad Salehi, MD, PhD

    Ahmad Salehi, M.D., Ph.D. is a Clinical Associate Professor at the Department of Psychiatry and Behavioral Sciences, Stanford Medical School and the Director of the Translational Laboratory at the VA Palo Alto Health Care System in California. He obtained his MD in Tehran, Iran ...

    See more See less
  • Paul Mathews, PhD

    Dr. Paul J. Mathews received his bachelors degree from the University of Oregon where he studied invertebrate behavioral plasticity in the lab of Dr. Nathan Tublitz. He received his Ph.D. in neuroscience from the University of Texas at Austin under the mentorship of Dr. Nace ...

    See more See less
  • Ulrich Hengst, PhD

    Dr. Ulrich Hengst studied biochemistry at the Ruhr University Bochum, Germany, and conducted his graduate research at the Friedrich Miescher Institute for Biomedical Research in Basel, Switzerland, in the group of Prof. Denis Monard. In 2003 he received his PhD from the ...

    See more See less
  • Anthony Grace, PhD

    Dr. Anthony A. Grace is a Distinguished Professor of Neuroscience and a Professor of Psychiatry and Psychology at the University of Pittsburgh in Pittsburgh, PA. He received his Ph.D. from Yale University School of Medicine with Dr. Benjamin S. Bunney and had postdoctoral ...

    See more See less
  • Pierre-Antoine Gourraud, PhD, MPH

    Pierre-Antoine Gourraud is a former student of the Ecole Normale Suprieure de Lyon in France. After receiving an M.P.H. from University Paris XIII in 2002, he got his Ph.D. in Immunogenetic Epidemiology and Public Health from Toulouse University in 2005. He relocated to the ...

    See more See less
  • Eric Gluck, MD, JD

  • Szczepan Baran, VMD, MS

    Dr. Szczepan Baran is the Global Head, Animal Welfare and Compliance Training at Novartis Institutes for Biomedical Research. Dr. Baran received a Bachelor of Science in Pre-Veterinary Medicine from the University of Delaware, a Veterinary Medical Doctoral degree from the ...

    See more See less
  • Ottavio Arancio MD, Ph.D

    Dr. Ottavio Arancio received his Ph.D and M.D. from the University of Pisa (Italy). From 1981 to 1986 he took residency training in Neurology at the University of Verona (Italy). Dr. Arancio has held Faculty appointments at Columbia University, NYU School of Medicine and at ...

    See more See less
  • R. Claudio Aguilar, Ph.D.

    Dr. Aguilar obtained his PhD degree in Immunochemistry from the School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina. Dr. Aguilar pursued his post-doctoral training at the National institutes of Health in Bethesda, MD in the lab of the well-known cell ...

    See more See less
  • Antonio Baines, PhD

    Dr. Antonio T. Baines is an Associate Professor in the Department of Biology at North Carolina Central University (NCCU) and an adjunct professor in the Department of Pharmacology in the School of Medicine at the University of North Carolina (UNC) Chapel Hill. He earned a ...

    See more See less
  • Pinar Bayrak-Toydemir, MD, PhD

    Dr. Bayrak-Toydemir is the medical director of the Molecular Genetics and Genomics Laboratories at ARUP and an associate professor of pathology at the University of Utah School of Medicine. Dr. Bayrak-Toydemir received her MD from the Ankara University School of Medicine in ...

    See more See less
  • Wieslaw Furmaga, MD

    Director, Clinical Chemistry Laboratory University Hospital Director, General Laboratory Cancer Treatment Research Center Director, Proteomics Laboratory UTHSC at San Antonio Interim Director, Molecular Laboratory UTHSC at San Antonio Associate Director, Mycology Laboratory UTHSC ...

    See more See less
  • George Fritsma, MS, MT

    George Fritsma is an associate professor in Laboratory Medicine of the Department of Pathology at the University of Alabama at Birmingham. Prof. Fritsma manages www.fritsmafactor.com, "The Fritsma Factor, Your Interactive Hemostasis Resource," a clinical coagulation ...

    See more See less
  • Bradley Ford, MD, PhD

    Bradley Ford received his M.D. and Ph.D. (Physiology and Biophysics) degrees from SUNY Stony Brook, followed by a Clinical Pathology residency and postdoctoral training in basic and clinical microbiology at Washington University in St. Louis. His research interests include ...

    See more See less
  • David Carpentieri, MD

  • Charles Cantor, PhD

    Dr. Charles Cantor is a founder, and Chief Scientific Officer at SEQUENOM, Inc., which is a genetics discovery company with tools, information and strategies for determining the medical impact of genes and genetic variations. He is also the founder of SelectX Pharmaceuticals ...

    See more See less
  • Cynthia Bowman MD

    Dr. Cynthia Bowman has been a broad based general pathologist for over 30 years. She graduated with a BA in Chemistry from St. Olaf College, received her MD from Vanderbilt University Medical School, and trained for 6 years at the University of California, San Francisco as a ...

    See more See less
  • Christoph H. Borchers, Ph.D.

    Dr. Borchers received his B.S., M.S. and Ph.D. from the University of Konstanz, Germany. After his post-doctoral training and employment as a staff scientist at NIEHS/NIH/RTP, NC and he was the director of the Duke - UNC Proteomics Facility and held a faculty position at UNC ...

    See more See less
  • Peter Blume-Jensen, MD, PhD

    Dr. Peter Blume-Jensen has extensive expertise in basic and translational cancer research, oncogenic signaling, and targeted oncology therapeutics drug discovery prior to joining Metamark as CSO in 2010.  From 2001 to 2008 Peter was department head at first Serono, US and ...

    See more See less
  • Josip Blonder, MD

    Dr. Blonder leads the Clinical Proteomics Group at the CRTP/FNL. FNL is a Federally Funded Research and Development Center operated by Leidos Biomedical Research, Inc., for the National Cancer Institute (NCI). In 1978, Dr. Blonder received his M.D. at the Rijeka University ...

    See more See less
  • Joan W Bennett, PhD

  • Tatjana Matejic, PhD, D(ABMLI)

MAR 19, 2015
Neuroscience
95 217 190268

BioConference Live makes it easier and more cost-effective for the neuroscience research community to come together online through live video webcasts and real-time networking. BioConference Live attendees learn new concepts, tools and techniques that they can apply to research and diagnosis. BioConference Live requires no travel or time away from the lab or hospital, yet delivers all the benefits of a physical conference. Attendees can earn free CME and CE Credits.

This years topics will include: Chemical Neuroanatomy, Emerging Therapies, Imaging Methods, Psychiatric Disorders; Autism, Multiple Sclerosis, Depression, Schizophrenia, OCD, Neurobiology, Anatomy, Basic Mechanisms, Techniques, Optogenetics, BRAIN initiative, Translational Neuroscience, and other topics.

This event will bring together research scientists, post docs, principal investigators, lab directors and professionals from around the world to learn about recent advances in neuroscience. This conference offers an amazing opportunity as it is free to participants, and there will be no out-of-pocket expenses for travel. However, participants will still benefit from interacting with a global community of like-minded colleagues, without leaving the comfort of their office or home.

Conference participants will be able to:

- Attend interactive live streaming video sessions
- Have their questions answered in real-time by industry experts
- Chat live with peers and speakers
- Browse a virtual exhibit floor for solution providers
- No crowded airports, delayed flights or expensive hotel rooms, but still the look and feel of a first-rate conference with world renowned experts.
- Participants also benefit from the fact that experts and vendors are more accessible, no more waiting in line to speak to someone.

Think it is too good to be true? Check out the venue and become a believer.


Speakers:
  • Professor Emeritus, The Scripps Research Institute
  • Distinguished Professor of Neuroscience, Professor of Psychiatry and Psychology Department of Neuroscience, University of Pittsburgh
  • Swedish Pharmacologist, Nobel Prize Winner
  • Head of Department of Psychology, Professor of Cognitive Neuroscience, University of Cambridge
  • McKenzie Foundation Chair in Psychiatry; Distinguished Chair in Psychiatric Research, Chair in Brain Science, Professor, UT Southwestern Medical Center
  • Professor of Psychiatric Research, Institute of Psychiatry, King's College London
  • Scientia Professor and Head of the School of Psychiatry, University of New South Wales
  • Radiology Vice Chair for Research Administration and Training, Professor of Radiology and Radiological Science, Johns Hopkins University School of Medicine
  • Professor, Department of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry
  • Director, NIMH Psychoactive Drug Screening Program, Michael Hooker Chair Protein Therapeutics , Professor of Pharmacology, UNC Chapel Hill Medical School Chapel Hill
  • Professor of Anatomy and Neurobiology, Washington University School of Medicine
  • Professor, Center for Psychiatric Neuroscience, Lausanne University Hospital
  • Director, National Institute of Neurological Disorders and Stroke
  • Program Manager of the Biological Technologies Office, DARPA
  • Principal Investigator, Picowar Institute, Assistant Professor of Neuroscience, Department of Brain and Cognitive Sciences, MIT

Show Resources
Agenda
All times are Pacific Time
  • MAR 18, 2015 06:00 AM PDT
    Speaker: Anthony Grace, PhD
  • MAR 18, 2015 07:30 AM PDT
    Speaker: Suzanne Haber, PhD
  • MAR 18, 2015 09:00 AM PDT
    Speaker: Bryan L. Roth, MD, PhD
  • MAR 18, 2015 10:30 AM PDT
    Speaker: Kim Quang Do, PhD
  • MAR 18, 2015 12:00 PM PDT
    Speaker: Carol Tamminga, MD
  • MAR 18, 2015 01:30 PM PDT
    Speaker: Floyd E. Bloom, M.D.
  • MAR 18, 2015 03:00 PM PDT
    Speaker: David Van Essen, PhD
  • MAR 19, 2015 06:00 AM PDT
    Speaker: Arvid Carlsson, MD, PhD
  • MAR 19, 2015 07:30 AM PDT
    Speaker: Sir Robin Murray, PhD
  • MAR 19, 2015 09:00 AM PDT
    Speaker: Trevor Robbins, CBE FRS FMedSci FBPsS
  • MAR 19, 2015 10:30 AM PDT
    Speaker: Dean Wong, MD, PhD
  • MAR 19, 2015 12:00 PM PDT
    Speaker: Philip Mitchell AM, MB BS (Hons I), MD, FRANZCP, FRCPsych
  • MAR 19, 2015 01:30 PM PDT
    Speaker: Kay Tye, PhD
  • MAR 19, 2015 03:00 PM PDT
    Speaker: Justin Sanchez, PhD
  • MAR 19, 2015 03:00 PM PDT
    Speaker: Walter Koroshetz, MD
  • Psychiatric Disorders
  • MAR 18, 2015 06:00 AM PDT
    Speaker: Anthony Grace, PhD
  • MAR 18, 2015 10:30 AM PDT
    Speaker: Kim Quang Do, PhD
  • MAR 18, 2015 12:00 PM PDT
    Speaker: Carol Tamminga, MD
  • MAR 19, 2015 07:30 AM PDT
    Speaker: Sir Robin Murray, PhD
  • MAR 19, 2015 12:00 PM PDT
    Speaker: Philip Mitchell AM, MB BS (Hons I), MD, FRANZCP, FRCPsych
  • Anatomy
  • MAR 18, 2015 07:30 AM PDT
    Speaker: Suzanne Haber, PhD
  • Techniques
  • MAR 18, 2015 09:00 AM PDT
    Speaker: Bryan L. Roth, MD, PhD
  • MAR 19, 2015 01:30 PM PDT
    Speaker: Kay Tye, PhD
  • Chemical Neuroanatomy
  • MAR 18, 2015 01:30 PM PDT
    Speaker: Floyd E. Bloom, M.D.
  • Neurobiology
  • MAR 18, 2015 03:00 PM PDT
    Speaker: David Van Essen, PhD
  • Emerging Therapies
  • MAR 19, 2015 06:00 AM PDT
    Speaker: Arvid Carlsson, MD, PhD
  • Translational
  • MAR 19, 2015 09:00 AM PDT
    Speaker: Trevor Robbins, CBE FRS FMedSci FBPsS
  • Imaging
  • MAR 19, 2015 10:30 AM PDT
    Speaker: Dean Wong, MD, PhD
  • The BRAIN Initiative
  • MAR 19, 2015 03:00 PM PDT
    Speaker: Justin Sanchez, PhD
  • MAR 19, 2015 03:00 PM PDT
    Speaker: Walter Koroshetz, MD
Speakers

  • Floyd E. Bloom, M.D.
    Professor Emeritus, The Scripps Research Institute
    Biography
      Floyd E. Bloom, M.D.is professor emeritus at The Scripps Research Institute in La Jolla, California. He was chairman emeritus of the department of neuropharmacology at The Scripps Research Institute, past president of the American Association for the Advancement of Science, former president of the Society for Neuroscience and of the American College of Neuropsychopharmacology, former editor-in-chief of Science (1995-2000), director of behavioral neurobiology at the Salk Institute for Biological Studies, and chief of the Laboratory of Neuropharmacology of the National Institute of Mental Health. Dr. Bloom recently won the RSA Lifetime Achievement Award at the Research Society on Alcoholisms annual meeting in June 2012 in San Francisco, California.
    • Anthony Grace, PhD
      Distinguished Professor of Neuroscience, Professor of Psychiatry and Psychology Department of Neuroscience, University of Pittsburgh
      Biography
        Dr. Anthony A. Grace is a Distinguished Professor of Neuroscience and a Professor of Psychiatry and Psychology at the University of Pittsburgh in Pittsburgh, PA.&nbsp; He received his Ph.D. from Yale University School of Medicine with Dr. Benjamin S. Bunney and had postdoctoral training with Dr. Rodolfo Llinas in the Department of Physiology and Biophysics at New York University School of Medicine.&nbsp; Dr. Grace has been involved in translational research related to the dopamine system for over 30 years.&nbsp;&nbsp; His early work pioneered the mode of action of antipsychotic drugs, and the identification and characterization of dopamine-containing neurons, and was the first to provide a means to quantify their activity state and pattern in a way that is the standard in the literature.&nbsp; His current work involves novel treatments for schizophrenia and its prevention, the role of dopamine in anhedonia and affective disorders, and the mode of action of ketamine and novel antidepressant drugs.&nbsp; Dr. Grace has received several awards for his research, including the Paul Janssen Schizophrenia Research Award and the Lilly Basic Scientist Award from the International College of Neuropsychopharmacology, the Efron Award from the American College of Neuropsychopharmacology, as well as a NIMH MERIT award, a Distinguished Investigator award from the National Alliance for Research in Schizophrenia and Depression, the Judith Silver Memorial Investigator Award from the National Alliance for the Mentally Ill, a Fellow of the American Association for the Advancement of Science, and appointment as a Distinguished Professor of Neuroscience at the University of Pittsburgh.&nbsp; He is also a past member of the governing council of the American College of Neuropsychopharmacology and is on the editorial board fornumerous leading journals in the field. <br />
      • Arvid Carlsson, MD, PhD
        Swedish Pharmacologist, Nobel Prize Winner
        Biography
          Arvid Carlsson, Swedish pharmacologist who, along with Paul Greengard and Eric Kandel, was awarded the 2000 Nobel Prize for Physiology or Medicine for his research establishing dopamine as an important neurotransmitter in the brain. Carlsson received a medical degree from the University of Lund in 1951 and subsequently held teaching positions there until 1959, when he became professor of pharmacology at the University of Gothenburg. When Carlsson began his pioneering studies in the 1950s, scientists thought that dopamine worked only indirectly, by causing brain cells to make another neurotransmitter, noradrenaline. Using a sensitive test that he had devised, Carlsson detected particularly high levels of the compound in areas of the brain that controlled walking and other voluntary movements. In animal experiments he showed that depletion of dopamine impairs the ability to move. When Carlsson treated dopamine-depleted animals with the amino acid l-dopa, the symptoms disappeared, and the animals moved normally again. This led to the use of l-dopa as a treatment for Parkinson disease, and it eventually became the single most important medication for the disease. Carlsson's work also contributed to an understanding of the relationship between neurotransmitters and mental states and led to the introduction of new antidepressant drugs.
        • Trevor Robbins, CBE FRS FMedSci FBPsS
          Head of Department of Psychology, Professor of Cognitive Neuroscience, University of Cambridge
          Biography
            Trevor Robbins was appointed in 1997 as the Professor of Cognitive Neuroscience at the University of Cambridge. He was elected to the Chair of Experimental Psychology (and Head of Department) at Cambridge from October 2002. He is also Director of the Behavioural and Clinical Neuroscience Institute (BCNI), jointly funded by the Medical Research Council and the Wellcome Trust. The mission of the BCNI is to inter-relate basic and clinical research in psychiatry and neurology for such conditions as Parkinson's, Huntington's, and Alzheimer's diseases, frontal lobe injury, schizophrenia, depression, drug addiction and developmental syndromes such as attention deficit/hyperactivity disorder. <br /> <br />Trevor is a Fellow of the British Psychological Society (1990), the Academy of Medical Sciences (2000) and the Royal Society (2005). In 2014 he was awarded a share of the Grete Lundbeck Brain Prize. He was also given the American Psychological Association's Distinguished contribution award in 2011. He has been President of the European Behavioural Pharmacology Society (1992-1994) and he won that Society's inaugural Distinguished Scientist Award in 2001. He was also President of the British Association of Psychopharmacology from 1996 to 1997. He has edited the journal Psychopharmacology since 1980 and joined the editorial board of Science in January 2003. He has been a member of the Medical Research Council (UK) and chaired the Neuroscience and Mental Health Board from 1995 until 1999. <br /> <br />He has been included on a list of the 100 most cited neuroscientists by ISI, has published over 600 full papers in scientific journals and has co-edited seven books (Psychology for Medicine: The Prefrontal Cortex; Executive and Cognitive Function: Disorders of Brain and Mind 2:Drugs and the Future: The Neurobiology of Addiction; New Vistas. Decision-making, Affect and Learning: and, Cognitive Search: Evolution, Algorithms, and the Brain). <br />
          • Carol Tamminga, MD
            McKenzie Foundation Chair in Psychiatry; Distinguished Chair in Psychiatric Research, Chair in Brain Science, Professor, UT Southwestern Medical Center
            Biography
              Dr. Tamminga holds the Lou and Ellen McGinley Distinguished Chair and the McKenzie Chair in Psychiatry at the University of Texas Southwestern Medical School and is the Chairman of the Department of Psychiatry and the Chief of the Translational Neuroscience Division in Schizophrenia at UTSW.&nbsp;&nbsp; She received her M.D. degree from Vanderbilt University and completed residency training in psychiatry at the University of Chicago.&nbsp; She served on the University of Chicago faculty from 1975 to 1979 and moved to the NINDS for training in Neurology in 1978.&nbsp;&nbsp; After joining the faculty at the University of Maryland Medical School in 1979, she practiced research, clinical care and teaching there until joining the faculty at UT Southwestern Medical School in 2003. <br /> <br />Dr. Tamminga is currently a member of NIMHs National Advisory Board and has served on the Board of Scientific Counselors of the National Institute of Mental Health and the National Institute of Drug Abuse, as Council member and President of the American College of Neuropsychopharmacology, as a Member and Chair of the Psychopharmacological Drugs Advisory Committee of the FDA, as well as consultant for the Orphan Products Development Review Group, FDA.&nbsp; She is a member of the Advisory Board of the Brain and Behavioral Research Foundation (NARSAD).&nbsp;&nbsp; She is currently the Deputy Editor of the American Journal of Psychiatry and on the editorial board of several other journals in the field.&nbsp;&nbsp; Dr. Tamminga was elected to the Institute of Medicine of the National Academies of Sciences in 1998 and has served on several IOM committees in that capacity. <br />
            • Sir Robin Murray, PhD
              Professor of Psychiatric Research, Institute of Psychiatry, King's College London
              Biography
                Robin Murray is Professor of Psychiatric Research at the Institute of Psychiatry, and indeed has spent most of his working life there apart from one year in the USA: fortunately the latter did not do him too much harm. His particular interest is in understanding the causes of psychosis, and he and his colleagues have contributed to the understanding that environmental factors such as obstetric events, heavy cannabis use and migration increase the risk of developing schizophrenia-like psychoses. He is also sees people with psychosis at the South London and Maudsley NHS Trust who are been referred from across the UK because they have not responded to treatment locally. He has written numerous articles, not all of the boring, and is the second most frequently cited psychiatrist outside the USA; he has supervised 52 PhDs and 35 of his students have become professors. He was elected a Fellow of the Royal Society in 2010 and received a knighthood in 2011.
              • Philip Mitchell AM, MB BS (Hons I), MD, FRANZCP, FRCPsych
                Scientia Professor and Head of the School of Psychiatry, University of New South Wales
                Biography
                  Philip Mitchell is Scientia Professor and Head of the School of Psychiatry at University of New South Wales in Sydney, Australia; Member, Australian National Health and Medical Research Council Research Committee; Vice-President (Governance), International Society for Bipolar Disorders; and Board Member, Black Dog Institute. His research and clinical interests are in bipolar disorder and depression, with a particular focus on: predictors of the development of bipolar disorder in at-risk individuals; molecular genetics of bipolar disorder; pharmacological and psychological treatments for bipolar disorder and depression; clinical phenomenology of bipolar disorder and depression; and neurostimulatory therapies for depression. Professor Mitchell has published over 450 peer-reviewed papers or book chapters and is lead investigator on an Australian NHMRC-funded Program Grant on depression and bipolar disorder. He serves on the editorial boards of ‘Psychiatric Genetics', ‘CNS Drugs', ‘CNS Spectrums', ‘Frontiers in Behavioral and Psychiatric Genetics', ‘Future Neurology', ‘International Journal of Bipolar Disorders', ‘Medicine Today' and ‘Therapeutic Advances in Psychopharmacology'. In 2002 he was awarded the Senior Research Award of the Royal Australian and New Zealand College of Psychiatrists (RANZCP). In 2004, he received the Founders Medal of the Australasian Society for Psychiatry Research. In 2008, he was invited to give the endowed Samuel Novey Lecture in Psychological Medicine at Johns Hopkins University, Department of Psychiatry and Behavioral Sciences. In the 2010 Australia Day honours list Professor Mitchell was appointed as a Member of the Order of Australia for service to medical education, particularly in the field of psychiatry, as an academic, researcher and practitioner, through contributions to the understanding, treatment and prevention of mental illnesses. In 2013 he was awarded the College Citation of the RANZCP for exceptional service to psychiatry.
                • Dean Wong, MD, PhD
                  Radiology Vice Chair for Research Administration and Training, Professor of Radiology and Radiological Science, Johns Hopkins University School of Medicine
                  Biography
                    Dr. Dean Foster Wong is a Professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. He also serves as Radiology Vice Chair for Research Administration and Training, and Director of the Section of High Resolution Brain PET Imaging within the Division of Nuclear Medicine. <br /> <br />Dr. Wong received his undergraduate degree in physics from the University of Western Ontario, and completed his M.D. at the University of Toronto in 1977. After an internship at Sunnybrook Medical Center in Toronto, he undertook a residency in anatomic pathology at Princess Margaret Hospital of the Ontario Cancer Institute, and a subsequent residency in radiology at the University of Toronto. <br /> <br />In 1980, he came to Johns Hopkins as a research and clinical fellow in the Radiology Division of Nuclear Medicine. He was soon promoted to Assistant Professor of Radiology, and in 1987 became an Associate Professor. He received a doctorate in Radiation Health Sciences from Hopkins in 1990. <br /> <br />Over the course of his career, Dr. Wong has been a leader in the design, development and use of PET scanning for the study of brain chemistry. He has been primary investigator on numerous federal and private grants, has authored or coauthored more than 200 articles and 50 book chapters and essays, and has been an active consultant to pharmaceutical companies. <br /> <br />In 2013, the Society of Nuclear Medicine and Molecular Imaging bestowed upon him the Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science. <br />
                  • Suzanne Haber, PhD
                    Professor, Department of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry
                    Biography
                      Dr. Habers research focuses on the neural network underlying learning and decision-making that leads to action plan development. The cortico-basal ganglia-thalamic system is central to this network and comprises a diverse group of structures involved in reward and motivation, cognition and motor control. Pathology of this network is implicated in several mental health disorders including drug addiction, obsessive-compulsive disorder, and schizophrenia. Her lab is addressing the hypothesis that cortico-basal ganglia connections are critical for integrating information across functional domains. The lab is also investigating which pathways are stimulated during deep brain stimulation, a therapy now being actively investigated for depression and obsessive-compulsive disorder and understanding postnatal changes in the cortico-basal ganglia system associated with specific developmental milestones and the high level of plasticity during early learning. <br /> <br />Dr. Haber received her Ph.D. in neuro-and bio-behavioral sciences from Stanford University. <br />
                    • Bryan L. Roth, MD, PhD
                      Director, NIMH Psychoactive Drug Screening Program, Michael Hooker Chair Protein Therapeutics , Professor of Pharmacology, UNC Chapel Hill Medical School Chapel Hill
                      Biography
                        Bryan L. Roth MD, PhD is the Michael Hooker Distinguished Professor of Protein Therapeutics and Translational Proteomics in the Department of Pharmacology at the University of North Carolina at Chapel Hill Medical School.&nbsp; Dr. Roth has published more than 300 papers and has given more than 200 invited talks. Dr. Roth has served on the editorial boards of many major scientific journals including the Journal of Biological Chemistry, Molecular Pharmacology, the Journal of Pharmacology and Experimental Therapeutics, ACS Medicinal Chemistry Letters, The Journal of Receptors and Signal Transduction Research, the Journal of Neurochemistry, Pharmacology and Therapeutics, Psychopharmacology and Neuropsychopharmacology.&nbsp; Dr Roth is currently Associate Editor for the Journal of Clinical Investiagation.&nbsp;&nbsp; Dr. Roth is also a member of Faculty of 1000. <br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br />Dr. Roth has received a number of honors including the PhRMA Foundation Excellence in Pharmacology Award, the Irving Page Lecture, the NARSAD Distinguished Investigator Award, the Heffter Foundation Award for Basic Science Research, the Lowenthal Lecture (Medical College of Virginia), a Prestige Lecture (Universit de Montral), the SG Fergusson Memorial Lecture (Robarts Institute), the Chauncy Leake Memorial Lecture (Univ Texas Medical Branch), the National Institute of Mental Health Career Development Award,&nbsp; a Dana Foundation Fellowship in Neurosciences (Stanford University) and Phi Beta Kappa (St. Louis University).&nbsp; Dr. Roths work has been highlighted and Dr. Roth has been interviewed about his work in the New York Times, the Wall Street Journal, National Public Radios All Things Considered, CBS Early Program, MSNBC, the Los Angeles Times and a large number of other media outlets. Dr. Roth was elected to the Institute of Medicine in 2014. <br />
                      • David Van Essen, PhD
                        Professor of Anatomy and Neurobiology, Washington University School of Medicine
                        Biography
                          Dr. Van Essen is currently Edison Professor and Head of the Anatomy & Neurobiology Department at Washington University in St. Louis. He has served as Editor-in-Chief of the Journal of Neuroscience, founding chair of the Organization for Human Brain Mapping, and President of the Society for Neuroscience. He is a fellow of the AAAS and has received the Peter Raven Lifetime Achievement Award from the St. Louis Academy of Science and the Krieg Cortical Discoverer Award from the Cajal Club. Dr. Van Essen received his undergraduate degree in Chemistry in 1967 from Caltech and his graduate degree in neurobiology in 1971 from Harvard. He was a postdoctoral fellow at Harvard under Drs. David Hubel and Torsten Wiesel and did additional postdoctoral work in Norway and England before returning to Caltech in 1976. He was a faculty member in the Division of Biology at Caltech until 1992, during which time he served as Executive Officer for Neurobiology (1982-1989) and Option Representative for the Computation and Neural Systems program (1986-1991). In 1992 he became Edison Professor of Neurobiology and Head of the Department of Anatomy and Neurobiology at Washington University School of Medicine. Dr. Van Essen is internationally known for his research on how the brain organizes and processes visual information. He has made extensive contributions to the understanding of how the brain perceives shape, motion and color and how attention affects neural activity. His work has helped to demonstrate that the brain contains dozens of different areas involved in vision and that these areas are interconnected by hundreds of distinct neural pathways. He and his colleagues have developed powerful new techniques in computerized brain mapping to analyze these visual areas in humans as well as nonhuman primates. This work includes the continued development of an integrated suite of software tools for surface-based analyses of cerebral cortex. These methods are applied to the analysis of cortical structure and function in humans, monkeys and rodents. A broad objective is to develop probabilistic surface-based atlases that accurately convey commonalities as well as differences between individuals.
                        • Kim Quang Do, PhD
                          Professor, Center for Psychiatric Neuroscience, Lausanne University Hospital
                          Biography
                            Following a career in basic research in chemistry, molecular biology and neurobiology (glutatmate and nitric oxide transmission, neuro Research Institute (Zurich University), I moved towards "bench to bed" research at the Center for Psychiatric Neuroscience (Department of Psychiatry, Lausanne University Hospital). I set up a translational research program aimed at a better understanding of the causes and mechanisms leading to schizophrenia phenotypes in order to develop markers for early diagnosis, new drug targets as well as preventive and therapeutic measures. Building on an innovative hypothesis, I could demonstrate that oxidative stress/redox dysregulation induced, among others, by glutathione (GSH) deficit, may represent a "hub" on which both genetic and environmental risk factors converge during neurodevelopment, leading to the impairment of neural connectivity and synchronization, and to cognitive deficits as observed in patients. These mechanisms have been comprehensively documented in experimental models. Based on these relevant neurobiological data, a precursor of GSH, N administered to chronic patients. This double blind, placebo controlled add trial with NAC showed a net improvement potentials (mismatch negativity), neural synchronization, and produced no side effects. These promising results led a new clinical trial with young patients during their first psychotic episode, paving the way for risk subjects. In addition to my research activities, I serve as director of the Unit of Research in Schizophrenia and director of the Center for Psychiatric Neuroscience, where we also work on professional education and cure of major psychiatric disorders.
                          • Walter Koroshetz, MD
                            Director, National Institute of Neurological Disorders and Stroke
                            Biography
                              Dr. Koroshetz was named Acting Director of NINDS in October, 2014.&nbsp; Prior to this appointment, he served as Deputy Director of NINDS since January, 2007, where he worked with the NINDS Director in program planning and budgeting, and overseeing Institute scientific and administrative functions. <br /> <br />Before joining NINDS, Dr. Koroshetz served as vice chair of the neurology service and director of stroke and neurointensive care services at Massachusetts General Hospital (MGH). He was also a professor of neurology at Harvard Medical School and has led neurology resident training at MGH since 1990. <br /> <br />A native of Brooklyn, New York, Dr. Koroshetz graduated from Georgetown University and received his medical degree from the University of Chicago. He trained in internal medicine at the University of Chicago and Massachusetts General Hospital. Dr. Koroshetz trained in neurology at MGH, after which he did post-doctoral studies in cellular neurophysiology at MGH and the Harvard neurobiology department. He joined the neurology staff, first in the Huntingtons Disease unit and then in the stroke and neurointensive care service. <br /> <br />As a member of the NINDS intramural review and oversight committees, Dr. Koroshetz has been involved in various NINDS symposia and clinical trials, and served as the Institutes representative to the American Neurological Associations Career Development Symposium. He was a member of the NINDS-chaired Brain Attack Coalition (BAC), a group of professional, voluntary and governmental entities dedicated to reducing the occurrence, disabilities, and death associated with stroke. <br />
                            • Justin Sanchez, PhD
                              Program Manager of the Biological Technologies Office, DARPA
                              Biography
                                Dr. Justin Sanchez joined DSO as a program manager in 2013. At DARPA, Dr. Sanchez will explore neurotechnology, brain science and systems neurobiology. <br /> <br />Before coming to DARPA, Dr. Sanchez was an Associate Professor of Biomedical Engineering and Neuroscience at the University of Miami, and a faculty member of the Miami Project to Cure Paralysis. He directed the Neuroprosthetics Research Group, where he oversaw development of neural-interface medical treatments and neurotechnology for treating paralysis and stroke, and for deep brain stimulation for movement disorders, Tourettes syndrome and Obsessive-Compulsive Disorder. <br /> <br />Dr. Sanchez has developed new methods for signal analysis and processing techniques for studying the unknown aspects of neural coding and functional neurophysiology. His experience covers in vivo electrophysiology for brain-machine interface design in animals and humans where he studied the activity of single neurons, local field potentials and electrocorticogram in the cerebral cortex and from deep brain structures of the motor and limbic system. <br /> <br />He has published more than 75 peer-reviewed papers, holds seven patents in neuroprosthetic design and authored a book on the design of brain-machine interfaces. He has served as a reviewer for the NIH Neurotechnology Study Section, DoDs Spinal Cord Injury Research Program and the Wellcome Trust, and as an associate editor of multiple journals of biomedical engineering and neurophysiology. <br /> <br />Dr. Sanchez holds Doctor of Philosophy and Master of Engineering degrees in Biomedical Engineering, and a Bachelor of Science degree in Engineering Science, all from the University of Florida. <br />
                              • Kay Tye, PhD
                                Principal Investigator, Picowar Institute, Assistant Professor of Neuroscience, Department of Brain and Cognitive Sciences, MIT
                                Biography
                                  Kay Tye began her education as an undergraduate research assistant at MIT from 1999-2003. She continued her studies at the University of California, San Francisco as a graduate student in Patricia Janaks lab studying electrophysiological properties of amygdala neurons both in vivo and ex vivo during reward-seeking behavior. Kay then did a short postdoc with Antonello Bonci, now the intramural director of NIDA, to study synaptic strength following reward learning, followed by a postdoc at Stanford University with Karl Deisseroth where she used novel optogenetic techniques to dissect the neural circuitry underlying psychiatric disease. Kay is currently an Assistant Professor at Massachusetts Institute of Technology in the Picower Institute for Learning and Memory, a member of the Department of Brain and Cognitive Sciences. She is also a NYSCF Neuroscience Robertson Investigator <br />
                                Sponsored By

                                For information on becoming a sponsor or exhibitor, please click here.


                                Help

                                General LabRoots Questions

                                For bugs, spam, technical support or questions please call +1-714-463-4673 or email support@labroots.com  
                                Contact us

                                Virtual Events and Webinars

                                Supported Configurations

                                • Operating System Internet Explorer Firefox Chrome Safari
                                  Vista IE8+ FF10+ Chrome15+
                                  Windows 7 IE8+ FF10+ Chrome15+
                                  Windows 8 IE10 FF10+ Chrome15+
                                  Mac OS X   FF10+ Chrome15+ Safari5.1+
                                • Cookie settings: session cookies enabled
                                • Browser configuration must have JavaScript enabled
                                • Adobe Flash player 10.2 or later

                                To watch our webinars and virtual events a modern browser such as Chrome, Firefox, Safari, or an updated version of Internet Explorer is required.

                                Internet Connection

                                • A minimum of 100Kbps is recommended for audio-only events
                                • A minimum of 300Kbps is recommended for speaker on-video events

                                Computer Equipment

                                • Screen Resolution: Minimum 1024x768
                                • Video Card: 65,000 colors minimum
                                • Sound card and speakers (or headphones) for hearing webcast in full format
                                • Audio Card: 16-bit minimum
                                • RAM: 512MB of free RAM

                                Firewall Protocol

                                • HTTP on port 80 or HTTPS on port 443
                                • Adobe RTMP on port 1935, 80, or 443 with automatic fall-back to RTMPT (RTMP tunneling) on ports 1935, 80 or 443
                                • RTMPE (RTMP encrypted) on ports 1935, 80 or 443

                                Work-At-Home Attendees

                                • If a corporate VPN is used, confirm that your network traffic is not directed over the company VPN. If it is, please turn off the VPN while attending the virtual event.

                                For A Seamless Experience

                                When using a mobile device, FREE Mobile Apps are available:

                                - For viewing Webinars:

                                - For viewing Virtual Events

                                Attendee Guide

                                • To learn more about how the virtual event works for attendees, download the Attendee Guide (PDF).

                                Virtual Event and Webinar Support:

                                Continuing Education (CME/CE) Support

                                Loading Comments...